# Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
Canonical URL: https://biopharmsignal.com/news/TPST/tempest-announces-interim-results-from-ongoing-redeem-1-trial-of-tpst-2003-preparing-for-potential-u-s-registrational-study-in-2026
Ticker: TPST
Company: Tempest Therapeutics
Source: Tempest Therapeutics
Published: 2026-02-25 12:59 EST
Original Source URL: https://ir.tempesttx.com
## Summary

100% complete response (CR) rate among all six efficacy evaluable patients Favorable safety profile with no Grade > 3 CRS or ICANS Prior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease 36 patients

## Article Body
100% complete response (CR) rate among all six efficacy evaluable patients Favorable safety profile with no Grade > 3 CRS or ICANS Prior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease 36 patients
## Recent Company News
- 2026-05-29 12:00 EST — [Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds](https://biopharmsignal.com/news/TPST/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds) — Source: Tempest Therapeutics
- 2026-05-14 20:15 EST — [Tempest Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/TPST/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Tempest Therapeutics
- 2026-05-06 11:00 EST — [Tempest Presents Clinical Update at ISCT 2026 Annual Meeting](https://biopharmsignal.com/news/TPST/tempest-presents-clinical-update-at-isct-2026-annual-meeting) — Source: Tempest Therapeutics
- 2026-04-29 12:00 EST — [Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting](https://biopharmsignal.com/news/TPST/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting) — Source: Tempest Therapeutics
- 2026-04-22 12:00 EST — [Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T](https://biopharmsignal.com/news/TPST/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t) — Source: Tempest Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)